Journal
CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume 90, Issue 4, Pages 519-531Publisher
WILEY
DOI: 10.1038/clpt.2011.179
Keywords
-
Categories
Funding
- National Institutes of Health Pharmacogenomics Research Network [U01 GM074492, U19 HL065962, U01 HL105198, K23 HL091120, AHA 10GRNT3750024]
Ask authors/readers for more resources
The past decade has seen substantial advances in cardiovascular pharmacogenomics. Genetic determinants of response to clopidogrel and warfarin have been defined, resulting in changes to the product labels for these drugs that suggest the use of genetic information as a guide for therapy. Genetic tests are available, as are guidelines for incorporation of genetic information into patient-care decisions. These guidelines and the literature supporting them are reviewed herein. Significant advances have also been made in the pharmacogenomics of statin-induced myopathy and the response to beta-blockers in heart failure, although the clinical applications of these findings are less clear. Other areas hold promise, including the pharmacogenomics of antihypertensive drugs, aspirin, and drug-induced long-QT syndrome (diLQTS). The potential value of pharmacogenomics in the discovery and development of new drugs is also described. In summary, pharmacogenomics has current applications in the management of cardiovascular disease, with clinically relevant data continuing to mount.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available